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TEP1 is a mammalian telomerase-associated protein with similarity to the Tetrahymena telomerase protein
p80. Like p80, TEP1 is associated with telomerase activity and the telomerase reverse transcriptase, and it
specifically interacts with the telomerase RNA. To determine the role of mTep1 in telomerase function in vivo,
we generated mouse embryonic stem (ES) cells and mice lacking mTep1. The mTep1-deficient (mTep12/2) mice
were viable and were bred for seven successive generations with no obvious phenotypic abnormalities. All
murine tissues from mTep12/2 mice possessed a level of telomerase activity comparable to that in wild-type
mice. In addition, analysis of several tissues that normally lack telomerase activity revealed no reactivation of
telomerase activity in mTep12/2 mice. Telomere length, even in later generations of mTep12/2 mice, was equiv-
alent to that in wild-type animals. ES cells deficient in mTep1 also showed no detectable alteration in telome-
rase activity or telomere length with increased passage in culture. Thus, mTep1 appears to be completely dis-
pensable for telomerase function in vivo. Recently, TEP1 has been identified within a second ribonucleoprotein
(RNP) complex, the vault particle. TEP1 can also specifically bind to a small RNA, vRNA, which is associated
with the vault particle and is unrelated in sequence to mammalian telomerase RNA. These results reveal that
TEP1 is an RNA binding protein that is not restricted to the telomerase complex and that TEP1 plays a
redundant role in the assembly or localization of the telomerase RNP in vivo.
Most eukaryotic chromosome ends are maintained by a ri-
bonucleoprotein (RNP) complex called telomerase. Telomer-
ase is a reverse transcriptase that uses an integral RNA com-
ponent to catalyze the addition of telomeric repeats to the 39
end of single-stranded telomeric DNA (8).
In many organisms, the telomerase complex is a large (750-
to 1,000-kDa) RNP containing an integral RNA, a reverse
transcriptase protein subunit, and several associated proteins.
The telomerase RNA component provides a template for telo-
mere DNA synthesis, and its essential role in telomerase ac-
tivity, telomere length maintenance, and chromosome stability
has been demonstrated in ciliates, yeast, and mice (2, 14–16,
29, 39, 42). The telomerase reverse transcriptase (TERT) was
first identified in the yeasts Saccharomyces cerevisiae (EST2)
andSchizosaccharomycespombe(trt11)andtheciliateEuplotesaedi-
culatus (p123) (32, 36) and subsequently in humans (hTERT)
(12, 25, 34, 36, 38). Mutations of conserved amino acids within
the reverse transcriptase domain of S. cerevisiae Est2 and in
human TERT result in the loss of telomerase activity (6, 12, 32,
38, 46). In rabbit reticulocyte lysates, human telomerase activ-
ity is reconstituted by the addition of human TERT (hTERT)
and the telomerase RNA (1, 46).
In addition to the presumed core telomerase components,
consisting of the telomerase RNA and TERT, several proteins
associated with telomerase activity have also been identified.
In humans, the “foldosome” proteins hsp90 and p23 and three
telomerase RNA binding proteins, dyskerin, L22, and hStau,
are each associated with telomerase activity in cell extracts (18,
28, 35). In S. cerevisiae, the Sm protein is necessary for the
stability of the yeast telomerase RNA (44), while three other
proteins, Est1, Est3, and Cdc13, are dispensable for telomerase
activity but are required for telomere length maintenance
(30, 33, 45). In the ciliate Tetrahymena thermophila, two pro-
teins that copurify with telomerase, p80 and p95 (4, 7, 10), bind
to telomerase RNA and telomeric DNA, although their precise
role in the Tetrahymena telomerase complex is not yet clear (4,
7).
The mammalian homolog of p80, TEP1, is associated with
telomerase activity in human, mouse, and rat immortalized-cell
extracts (11, 37). The amino-terminal 900 amino acids of
TEP1, which contain the region homologous to Tetrahymena
p80, also interacted with telomerase RNA in an in vivo RNA-
protein interaction assay (11). Despite its association with telo-
merase components, the role of TEP1 in telomerase function is
unknown. Recently, TEP1 has also been identified as a com-
ponent of a large cytoplasmic RNP termed the vault particle
(24). The genetic characterization of these proteins is critical
to our understanding of the complexity, composition, and reg-
ulation of telomerase in vivo. We utilized homologous recom-
bination to disrupt the first mammalian telomerase-associated
protein to be identified, mTep1, in mice and embryonic stem
(ES) cells and analyzed the effects on telomerase activity and
telomere length maintenance.
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Construction of a murine Tep1 targeting vector. To isolate murine Tep1
genomic fragments, a mouse Tep1 BACMID genomic DNA clone was obtained
from Genome Systems Inc. (St. Louis, Mo.) and a full-length mTep1 cDNA
probe was used. Two genomic KpnI/SphI fragments (approximately 6.3 and 2.3
kb) of the mTep1 BACMID DNA hybridized to a cDNA probe spanning a region
containing the first third of the mTep1 open reading frame. These fragments
were subcloned into pSPORT (Stratagene). A targeted construct was designed to
replace four exons of mTep1 with the neomycin resistance gene. In brief, PCR
primers (59-CTCGAGGTTCGTAGGGTCAATGGTGTGTC-39 [sense] and 59-
GTCGACATTTCTGTGTTCAAGACAAATCAG-39 [antisense]) were used to
amplify a 3.7-kb long-arm fragment from the 6.3-kb mTep1 genomic clone using
the Expand long template PCR system (Boehringer Mannheim). Similarly, an
;770-bp short arm was amplified from the 2.3-kb mTep1 genomic clone using the
PCR primers 59-TCTAGATAGGTGGCGTTGATCGGTGATCG-39 (sense)
and 59-GCGGCGGCAACCTTTTGAAGAACAACCAATG-39 (antisense).
Targeted disruption of the mTep1 gene in ES cells. The mTep1 targeting vector
was linearized with NotI at the short arm and electroporated into E14 ES cells
(derived from the R129J strain). After G418 selection (0.3 mg/ml), homologous
recombinants were identified by PCR and confirmed by Southern blot analysis,
following published protocols (9). Primer TEP1-1, which is specific for the
deleted portion of mTep1, was used to detect the wild-type allele and primer
TEP1-2 was used to detect the mutant allele, while primer TEP1-3 was used to
detect both the wild-type and mutant alleles of mTep1. PCR amplification was
carried out with 30 cycles of 94°C for 1 min, 62°C for 1 min, and 72°C for 1 min.
The sequences of the above primers are as follows: TEP1-1, 59-CCAGCAGTA
TGAGGGTCGTCAGTGG-39; TEP1-2, 59-GCTAAAGCGCATGCTCCAGA
C-39; and TEP1-3, 59-CACATGCCTGTCTGGTTCTGTGGAG-39.
Homologous recombination of the targeting vector with the endogenous locus
results in insertion of a novel SpeI site into the mTep1 locus, thus allowing the
targeted and wild-type alleles to be distinguished by Southern analysis with a
probe corresponding to DNA just 39 to the short arm. Genomic DNA was
FIG. 1. Disruption of the murine Tep1 gene in ES cells and mice. (A) Schematic representation of homologous recombination of the targeting vector with the
endogenous locus. Insertion of a new Spe1 site into the targeted locus allows the targeted and wild-type alleles to be distinguished by Southern blot analysis with the
indicated 39 flanking probe. S, SpeI; N, Not1. (B) Detection of targeted and wild-type mTep1 alleles by Southern blot analysis of DNA from G1 mice. DNA was digested
with SpeI and hybridized with the probe shown in panel A. The 5.1-kb SpeI fragment corresponding to the wild-type allele is decreased to 1.6 kb upon disruption of
the locus by integration of the Neor gene. (C) Immunoblot of MEF extracts probed with an anti-TEP1 antibody (12). The position of the mTep1 protein is indicated.
The first lane contains human 293 cell lysate transfected with a recombinant hTEP1 plasmid (293-hTEP1). The protein species below the 85-kDa protein marker in
each immunoprecipitate is not specific to anti-TEP1 antibody.
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digested with SpeI, resolved on an agarose gel, transferred to a membrane, and
hybridized to the mTep1 genomic 39 flanking fragments.
Generation of mTep1-deficient mice and ES cells. Chimeric mice were pro-
duced by microinjection of three independent mTep11/2 ES cell clones into E3.5
C57BL/6J blastocysts and transferred to ICR pseudopregnant foster mothers.
Chimeric males were mated with C57BL/6J females (Jackson Laboratory). Germ
line transmission of the mutant allele was confirmed by PCR and Southern blot
analysis of tail DNA from mice with an agouti coat color. The mating strategy for
the mTep12/2 mice was the same as that used for the generation of the telome-
rase RNA-deficient mice (2). In brief, the first generation of mTep12/2 homozgy-
ous animals were referred to as G1, and the subsequent generations (obtained by
mating two mTep12/2 animals of an equivalent generation but derived from a
different founder) were G2, G3, etc. mTep12/2 ES cell clones were generated
from G418-resistant mTep11/2 ES cell clones by culturing with an increased
G418 concentration (4 mg/ml). ES cell culture was carried out as previously
described (9).
Cell lysate preparation and telomerase assays. S-100 extracts from cultured
cells and freshly dissected mouse tissues were prepared as described previously
(41). Cells lysed in a buffer containing 0.5% CHAPS {3-[(3-cholamidopropyl)-
dimethylammonio]-1-propanesulfonate} were prepared as described elsewhere
(26) (Intergen, Inc.). Telomerase activity was assayed using the telomeric repeat
amplification protocol (TRAP) assay following the manufacturer’s instructions
FIG. 2. Telomerase activity of mTep1-deficient tissues. (A) TRAP was performed for 25 cycles on testis tissue extracts of the indicated genotype. R, RNase A
treatment of the sample. An internal PCR standard for TRAP is shown at bottom right. The amounts of testis extract used was as follows: 4 mg of extract plus RNase
A (wild-type testis), or 4, 2, 1, and 0.5 mg of testis extract. (B) The conventional telomerase elongation assay was performed on murine liver and testes. A
telomerase-positive human cell extract (Raji) is shown as a positive control. The arrow indicates the position of telomerase elongation products from mouse tissue
extract, which were sensitive to RNase A treatment (R). The amount of extract used for each sample was 15 or 7.5 mg.
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(26) (Intergen, Inc.). The standard elongation assay for telomerase activity was
performed on S-100 extracts after fractionation on DEAE-agarose columns as
described previously (5, 40).
Immunoprecipitation analysis of mTep1. Immunoprecipitation analysis using
an affinity-purified anti-TEP1 polyclonal rabbit antibody was performed as de-
scribed previously (12). The specificity of the TEP1 polyclonal antibody was
confirmed by Western analysis using cell extracts from human 293 cells overex-
pressing recombinant hTEP1 and using a glutathione transferase-mTEP1 recom-
binant purified fusion protein (12).
Telomere length measurements by FISH. The average telomere fluorescence
at chromosome ends in splenocytes, thymocytes, and ES cells was measured by
using fluorescence in situ hybridization (FISH) combined with flow cytometry
(Flow-FISH) (43), with minor modifications. A telomere-specific fluorescein
isothiocyanate-conjugated (CCCTAA)3 peptide nucleic acid probe (0.3 mg/ml)
(Perseptive Biosystems) was employed. Telomere fluorescence is expressed as
molecules of equivalent soluble fluorochrome (MESF) (13).
Metaphase spreads, FISH and image analyses of ES cells, and mouse embryo
fibroblast (MEF) cultures were performed as described elsewhere (2, 47). The
Cy-3-labeled (CCCTAA)3 peptide nucleic acid was used as a probe.
RESULTS
Targeted disruption of mTep1 genes. The mTep1 targeting
strategy was designed to disrupt a region of mTep1 that is
required for binding to the murine telomerase RNA in a yeast
three-hybrid interaction assay (11) (Fig. 1A). Three separate
heterozygote mTep1 (mTep11/2) ES cell clones were used to
generate mTep11/2 founder mice (data not shown). One of the
mTep11/2 ES cell clones was used to generate three nullizy-
gous mTep1 (mTep12/2) clones. Different mTep11/2 founders
were bred together to generate mTep12/2 mice (Fig. 1B). The
mTep12/2 mice were designated as generation 1 (G1), and the
progeny of G1 cousins were defined as G2, et cetera, as de-
scribed previously (2). Seven generations (to G7) of mTep12/2
mice were fertile and showed no obvious phenotypic defects
compared to wild-type mice. Northern analysis of poly(A)1
mRNA from several mTep12/2 mouse tissues showed no de-
tectable transcripts upon hybridization to a full-length mTep1
cDNA probe (data not shown). Analysis of cell extracts pre-
pared from mTep12/2 G1 MEFs with an affinity-purified
anti-TEP1 rabbit polyclonal antiserum (spf2) revealed no
detectable mTep1 protein in lysates or anti-TEP1 immuno-
precipitation from mTep1-deficient mouse tissues (Fig. 1C and
data not shown).
mTep1 is not essential for telomerase catalysis in vivo. To
determine the role of mTep1 in telomerase catalysis, we ex-
amined mTep1-deficient ES cells, MEF cultures derived from
G1 mTep12/2 embryos, and several tissues from mTep12/2
mice (up to G3) for telomerase activity. In both the conven-
tional telomerase elongation assay and the PCR-based telome-
rase assay (TRAP) (26), all three independently derived
mTep12/2 ES cell clones possessed levels of telomerase activity
similar to those in the mTep11/2 clone and the parental line
(data not shown). We also tested whether telomerase activity
was altered in tissues from mTep12/2 mice. Telomerase activ-
ity was not significantly altered in testes, liver, kidney, lung, or
thymus tissue from mTep12/2 mice compared to wild-type
mouse tissues (Fig. 2A and Table 1). Subsequent analysis of
several tissues that normally lack telomerase activity, including
brain, skin, heart, and spleen (2, 41), revealed no reactivation
of telomerase activity in these tissues from mTep12/2 mice
(Table 1 and data not shown). In MEFs derived from G1
mTep12/2 embryos, there was also no significant change in
telomerase activity compared to that in the mTep11/2 and
wild-type MEFs (Table 1 and data not shown). In the conven-
tional telomerase assay, we did not detect any changes in telo-
merase activity levels in liver or testis extracts from
mTep12/2 mice (Fig. 2B).
The role of mTep1 in telomere length regulation in vivo.
Mice and ES cells disrupted in the telomerase RNA compo-
nent lack telomerase activity and undergo telomere attrition in
vivo (2, 16, 29, 39). In S. cerevisiae, EST1, EST3, and CDC13
are not required for telomerase activity (31); however, muta-
tion or disruption of these genes results in progressive telo-
mere loss (30, 31). To determine whether loss of mTep1 could
be essential for telomere length maintenance, we analyzed
telomere length in mTep1-deficient mice and ES cells.
To examine telomere length in a total cell population, we
used a quantitative method called Flow-FISH (43). We ob-
served that none of the mTep11/2 and three independent
mTep12/2 ES cell clones showed significant changes in average
telomere fluorescence intensity, regardless of increasing pop-
ulation doublings, compared to early or late passages of wild-
type cells (Fig. 3A). Thymocytes and splenocytes derived from
different generations of mTep1-deficient mice (G1 to G7) also
yielded very similar measurements of relative telomere lengths
that were comparable to those of the G1 mTep1 heterozygote
control (Fig. 3B and data not shown). The overall distribution
of telomere signal fluorescence in the G1 and G7 samples was
similar to that in the heterozygous mTep1 control (data not
shown). Similarly, FISH analysis of metaphase chromosome
preparations from mTep1-deficient MEFs showed no signifi-
cant change in telomere signal intensity or chromosomal ab-
errations compared to the wild-type MEFs (Fig. 4). We there-
fore conclude that disruption of mTep1 had no effect on either
the distribution or mean length of telomeres.
DISCUSSION
In mammals, the first genetic evidence for the essential role
of telomerase activity in telomere length maintenance was
elegantly demonstrated in mice lacking the telomerase RNA
component (2, 14–16, 29, 39, 42). In this study, we have used a
genetic approach to examine the role of the first identified
mammalian telomerase-associated protein, mTep1, in telome-
rase catalysis and telomere length regulation in vivo.
Despite the fact that TEP1 is associated with the telomerase
RNA and the telomerase catalytic subunit TERT in cell ex-
tracts from immortalized human, mouse, and rat cells, mTep1-
deficient mice show no significant alteration in telomerase
activity or telomere length. These results indicate that mTep1
is not essential for the catalytic activity of the telomerase com-
plex, at least as measured by the in vitro elongation assay, and
that as observed when deleted alone, mTep1 is not required for
telomere length maintenance. These results are consistent with
our previous finding from an in vitro assay that the reconsti-




Wild type 1/2 2/2
ES cells Strong Unchanged Unchanged
Primary MEFs Strong Unchanged Unchanged
Testes Strong Unchanged Unchanged
Liver Strong Unchanged Unchanged
Thymus Strong Unchanged Unchanged
Lung Weak Unchanged Unchanged
Kidney Weak Unchanged Unchanged
Heart Undetectable Undetectable Undetectable
Brain Undetectable Undetectable Undetectable
Skin Undetectable Undetectable Undetectable
Spleen Undetectable Undetectable Undetectable
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tution of human telomerase activity does not require the ad-
dition of hTEP1 (1).
Several possibilities could account for the absence of a telo-
merase-associated phenotype in mTep12/2 mice. Since mTep1
is associated with telomerase activity in immortalized cells, it is
possible that it plays a specific role in the function of telome-
rase in immortalized cells but not in normal cells (11). Another
possibility is that if TEP1 is associated with only a fraction of
the total telomerase activity in vivo, its disruption might have
no overt phenotypic consequences. A substoichiometric asso-
ciation of TEP1 with telomerase activity is suggested by the
observation that antibodies against TEP1, hStau, and L22 are
FIG. 3. Relative telomere lengths in ES cells and in splenocytes and thymocytes derived from mouse tissues, determined by Flow-FISH. (A) Average telomere
fluorescence in early (p1) and later (p10 and p20) passages of ES cells, including wild type, mTep11/2, and three mTep12/2 clones. Each MESF value represents the
results for one individual ES clone at the indicated passage; hence, there are no error bars. (B) Average telomere fluorescence in splenocytes and thymocytes derived
from early and late generations (G1 through G7) of mTep12/2 mice. In each set, data were pooled from at least five mice (error bars represent standard deviations).
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each able to immunoprecipitate telomerase activity, but not
each other, from human immortalized cell extracts (28). Alter-
natively, other telomerase RNA binding proteins may share a
redundant role with mTep1 in telomerase function. In Tetra-
hymena, both p80 and p95 synergistically bind to the telome-
rase RNA (4, 7). A mammalian homolog of p95 has not yet
been identified. In mammals, two additional telomerase RNA
binding proteins, L22 and hStau, were cloned using a yeast
three-hybrid screen (28). These proteins are each associated
with telomerase activity and hTERT, and yet there is no evi-
dence of a direct association with each other or with TEP1
(28). Whether separate telomerase complexes containing dis-
tinct telomerase RNA binding proteins share overlapping
functions in vivo has yet to be determined. Indirect immuno-
fluorescence analysis of TEP1 and TERT will be instrumental
in demonstrating whether TEP1 indeed colocalizes with a sub-
set of hTERT in intact cells.
Not all telomerase-associated proteins appear to be re-
stricted to the telomerase complex. At least some fraction of
human telomerase activity is associated with p23 and Hsp90,
two components of the ubiquitous foldosome which facilitate
assembly of the active telomerase complex in rabbit reticulo-
cyte lysates (18). TEP1 is expressed in many tissues, including
those that lack telomerase activity, suggesting that TEP1 may
be important for other cellular functions. In support of this
notion, TEP1 has also recently been discovered to be an inte-
gral component of a large cytoplasmic (13-MDa) RNP com-
plex referred to as the vault particle (24). Vault particles have
been isolated from a number of organisms and appear to be
ubiquitous among eukaryotes (19). Although the function of
the vault particle is unknown, several recent reports have im-
plicated the particle in intracellular transport (3, 17, 20, 27).
Purified vaults display an eight-fold, barrel-like symmetry and
contain at least three components in addition to TEP1, includ-
ing the 104-kDa major vault protein MVP (21), a 193-kDa
poly(ADP-ribosyl) polymerase called VPARP (23), and a
small RNA called vRNA (20, 22). TEP1, but not telomerase
activity, copurifies with the vault particle, and several vRNAs
specifically interact with TEP1 in the yeast RNA-protein in-
teraction assay (24). The so-called subunit sharing of the TEP1
protein between two seemingly unrelated RNPs suggests that
TEP1 may play a more general role in RNP structure, function,
or assembly. It is thus possible that TEP1 is a part of other
RNPs in addition to the vault and telomerase complexes. Le
and colleagues have also proposed that the telomerase RNA
binding proteins hStau and L22 might be involved in aspects of
RNA processing or RNP assembly that are not limited to
telomerase (28). While the absence of a direct role for telo-
merase is confounding, the generation of mTep1-deficient mice
is a first step toward the genetic dissection of the relationship
between telomerase and the assembly and regulation of other
cellular RNP complexes. We are currently examining mTep1-
deficient mice for the role of TEP1 in vaults and for the
possible involvement of TEP1 in other RNPs. In addition, the
generation of mice deficient in other telomerase-associated
components will enable us to ascertain whether TEP1 is ge-
netically redundant with other telomerase RNA binding pro-
teins for telomerase function in vivo.
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